☰ Sidebar
Voting period for this idea type has passed

SXSW Interactive 2013

Unlikely Allies: Marketing and Legal Unite!

Fostering innovation within highly regulated industries, like pharmaceutical marketing and financial services is a huge challenge. Marketing, technology, and digital teams often bring ideas to the table that legal and regulatory specialists have never even encountered before. Add in ambiguous regulations, recent enforcement actions, and frequent acquisitions and you have a chasm between what the brand wants to do and what the legal teams are comfortable with.

What to do, but butt (department) heads?

In this panel, we bring together people who’ve cracked the code on innovating in highly-regulated environments. From building collaborative workshops to setting new industry standards to cross-training teams, this group has introduced bold new ways to close the divide.

They’ll combine war stories and makeovers with new interviews and questions from both legal teams and marketing suites. They'll make you laugh, cringe, and go at an old problem with an entirely new perspective.

Share this idea


  1. When (and how) is the best way to bring a regulatory team into an innovative project?
  2. The penalties for non-compliance must be pretty big based on the conservative actions of our review committees. What are some of the penalties if we do not comply with all medical and legal requirements?
  3. How can I get legal teams to care about marketing? We don’t even speak the same language.
  4. What are some of the toughest questions you’ve ever been asked by legal and regulatory - and, how did you address them?
  5. What are some of the biggest missteps you’ve made along the way? What would you have done differently in retrospect?



Saul Morse, VP Multichannel Integration, Palio

Meta Information:

  • Tags: innovation
  • Event: Interactive
  • Format: Panel
  • Track: Health and Medicine
  • Level: Advanced
Show me another idea

Add Comments

comments powered by Disqus

SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.